Form 4: Boundless Bio Director, James Christensen, Acquires Stock Options
SEC Form 4 Filing
James Christensen, a director of Boundless Bio, Inc., acquired stock options on March 27, 2024, according to a Form 4 filing with the SEC.
Summary
- James Christensen, a director of Boundless Bio, Inc. (BOLD), filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on March 27, 2024, where Christensen acquired 13,219 stock options.
- These options vest in 36 substantially equal monthly installments starting April 27, 2024, and expire on March 26, 2034.
- The exercise price of the stock options is $16.
- Following the reported transaction, Christensen directly owns 13,219 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral filing indicating a standard stock option grant to a company director. It doesn't inherently suggest positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/27/2024 | Date of stock option acquisition |
| 04/27/2024 | First vesting date of the stock options |
| 03/26/2034 | Expiration date of the stock options |
| 03/29/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.